|
|
|
 09/10/2009
Sinobiopharma gets Chinese SFDA approval for use of Gabexate Mesylate
Sinobiopharma, a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China has received a certificate for the use of Gabexate mesylate as a pharmaceutical raw material from the Chinese State Food and Drug Administration
|
| |
|
Sinobiopharma, a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China has received a certificate for the use of Gabexate mesylate as a pharmaceutical raw material from the Chinese State Food and Drug Administration (SFDA).
Gabexate Mesylate is a serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin. Sinobiopharma is now awaiting GMP certification to manufacture Gabexate mesylate.
Known as Dong Ying Pharmaceutical in China, Sinobiopharma’s current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs. |
|
|
|
|
